aRibP N H | aRibP R 0 | aRibP R 1 | aRibP R 2 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clinical data | All patients (n= 163) | Positive (n= 30) | Negative (n= 133) | P value | Positive (n= 34) | Negative (n= 129) | P value | Positive (n= 24) | Negative (n= 139) | P value | Positive (n= 28) | Negative (n= 135) | P value |
Demographics | |||||||||||||
Age in years,b median | 37.0 | 36.5 | 37.0 | 0.317 | 35.0 | 37.0 | 0.081 | 35.0 | 37.0 | 0.326 | 37.0 | 37.0 | 0.467 |
Age at onset,c <18 years, % | 19.7 | 15.6 | 13.9 | 1.000 | 24.3 | 16.8 | 0.338 | 22.2 | 17.7 | 0.592 | 26.7 | 16.7 | 0.203 |
Females,c % | 89.8 | 84.4 | 91.2 | 0.324 | 89.2 | 90 | 1.000 | 96.3 | 88.7 | 0.314 | 90 | 89.9 | 1.000 |
SLE duration in months,b median | 108.0 | 97.0 | 109.0 | 0.716 | 69.0 | 109.0 | 0.118 | 62.0 | 109.0 | 0.147 | 96.0 | 107.0 | 0.756 |
ACR criteria | n = 163 | n = 30 | n = 133 | n = 34 | n = 129 | n = 24 | n = 139 | n = 28 | n = 135 | ||||
Number of ACR criteria,b median | 6.00 | 7.00 d | 6.00 d | 0.031 d | 7.00 | 6.00 | 0.059 | 6.50 | 6.00 | 0.236 | 7.00 | 6.00 | 0.076 |
Malar rash,c % | 66.2 | 73.3 | 64.6 | 0.402 | 70.6 | 65.1 | 0.684 | 70.8 | 65.5 | 0.815 | 71.4 | 65.2 | 0.662 |
Discoid rash,c % | 12.3 | 16.7 | 11.3 | 0.536 | 14.7 | 11.6 | 0.571 | 16.7 | 11.5 | 0.501 | 25.0 | 9.63 | 0.0504 |
Photosensitivity,c % | 46.6 | 63.3 d | 42.9 d | 0.046 d | 58.8 | 43.4 | 0.125 | 62.5 | 43.9 | 0.121 | 53.6 | 45.2 | 0.533 |
Oral ulcers,c % | 18.4 | 23.3 | 17.3 | 0.441 | 23.5 | 17.1 | 0.456 | 12.5 | 19.4 | 0.573 | 17.9 | 18.5 | 1.000 |
Arthritis,c % | 84.1 | 90.0 | 82.7 | 0.417 | 94.1 | 81.4 | 0.111 | 91.7 | 82.7 | 0.373 | 96.4 | 81.5 | 0,0506 |
Serositis,c % | 44.2 | 36.7 | 45.9 | 0.419 | 38.2 | 45.7 | 0.561 | 41.7 | 44.6 | 0.828 | 39.3 | 45.2 | 0.677 |
Renal disorder,c % | 42.9 | 46.7 | 42.2 | 0.686 | 44.1 | 42.6 | 1.000 | 37.5 | 43.9 | 0.658 | 39.3 | 43.7 | 0.834 |
Epilepsy or psychosis,c % | 12.9 | 20.0 | 11.3 | 0.228 | 14.7 | 12.4 | 0.774 | 25.0 | 10.8 | 0.091 | 21.4 | 11.1 | 0.209 |
Hematologic,c % | 63.8 | 70.0 | 62.4 | 0.530 | 67.6 | 62.8 | 0.690 | 58.3 | 64.7 | 0.646 | 67.9 | 62.9 | 0.672 |
Immune disorder and ANA, % | 100 | 100 | 100 | - | 100 | 100 | - | 100 | 100 | - | 100 | 100 | - |
SLEDAI | n = 101 | n = 17 | n = 84 | n = 22 | n = 79 | n = 17 | n = 84 | n = 17 | n = 84 | ||||
SLEDAI,b median | 6.00 | 6.00 | 6.00 | 0.517 | 6.00 | 6.00 | 0.886 | 6.00 | 6.00 | 0.915 | 6.00 | 6.00 | 0.256 |
Vasculitis,c % | 7.92 | 5.89 | 8.33 | 1.000 | 4.55 | 8.86 | 0.682 | 11.8 | 7.14 | 0.621 | 5.89 | 8.33 | 1.000 |
Arthritis,c % | 33.7 | 23.5 | 35.7 | 0.408 | 22.7 | 36.7 | 0.309 | 11.8 d | 38.1 d | 0.048 d | 11.8 d | 38.1 d | 0.048 d |
Hematuria,c % | 6.93 | 11.8 | 5.95 | 0.335 | 4.55 | 7.59 | 1.000 | 0.00 | 9.52 | 0.346 | 0.00 | 9.41 | 0.346 |
Proteinuria,c % | 9.90 | 17.6 | 8.33 | 0.366 | 9.09 | 10.1 | 1.000 | 5.88 | 10.7 | 1.000 | 5.88 | 10.7 | 1.000 |
Exanthema,c % | 32.7 | 11.8 | 36.9 | 0.0503 | 27.3 | 34.2 | 0.615 | 23.5 | 34.5 | 0.572 | 23.5 | 34.5 | 0.572 |
Alopecia,c % | 16.8 | 23.5 | 15.5 | 0.478 | 27.3 | 13.9 | 0.195 | 17.6 | 16.7 | 1.000 | 17.6 | 16.7 | 1.000 |
Pericarditis,c % | 6.93 | 5.88 | 7.14 | 1.000 | 9.09 | 6.33 | 0.645 | 11.8 | 5.95 | 0.335 | 5.88 | 7.14 | 1.000 |
Complement deficiency,c % | 57.4 | 64.7 | 55.9 | 0.597 | 68.2 | 51.2 | 0.331 | 58.8 | 57.1 | 1.000 | 64.7 | 55.9 | 0.597 |
Fever,c % | 3.96 | 0.00 | 4.67 | 1.000 | 4.55 | 3.79 | 1.000 | 0.00 | 4.76 | 1.000 | 0.00 | 4.76 | 1.000 |
Drugs | |||||||||||||
Prednisolone,c % | 89.9 | 93.1 | 89.2 | 0.738 | 90.9 | 89.7 | 1.000 | 86.9 | 90.4 | 0.706 | 88.9 | 90.3 | 0.734 |
Azathioprine,c % | 30.8 | 27.6 | 31.5 | 0.825 | 36.4 | 29.4 | 0.526 | 17.4 | 33.1 | 0.151 | 29.6 | 31.1 | 1.000 |
Cyclophosphamide,c % | 8.81 | 6.89 | 9.23 | 1.000 | 12.1 | 7.94 | 0.491 | 18.8 | 7.75 | 0.155 | 11.1 | 8.33 | 0.708 |
Mycophenolate mofetil,c % | 20.5 | 20.7 | 19.7 | 1.000 | 15.2 | 22.2 | 0.474 | 30.4 | 19.1 | 0.265 | 22.2 | 20.5 | 0.799 |
Methotrexate,c % | 3.04 | 3.23 | 3.01 | 1.000 | 8.33 | 1.56 | 0.071 | 7.69 | 2.17 | 0.179 | 3.45 | 2.96 | 1.000 |
Hydroxychloroquine sulfate,c % | 35.4 | 50.0 | 32.3 | 0.085 | 36.4 | 35.2 | 1.000 | 30.4 | 36.3 | 0.645 | 37.0 | 35.1 | 0.829 |
Laboratory | |||||||||||||
Leukocytes,b median | 6.50 | 7.03 | 6.40 | 0.539 | 7.00 | 6.30 | 0.136 | 6.58 | 6.40 | 0.479 | 6.50 | 6.49 | 0.933 |
Lymphocytes,b median | 0.87 | 0.67 | 0.87 | 0.164 | 0.63 d | 0.92 d | 0.036 d | 0.91 | 0.86 | 0.957 | 0.70 | 0.93 | 0.076 |
Monocytes,b median | 0.35 | 0.34 | 0.35 | 0.769 | 0.33 | 0.35 | 0.584 | 0.48 | 0.35 | 0.301 | 0.31 | 0.35 | 0.540 |
ALT,b,e median | 19.4 | 14.4 | 20.0 | 0.501 | 22.0 | 19.2 | 0.824 | 20.7 | 19.0 | 0.661 | 14.7 | 20.0 | 0.547 |
AST,b,e median | 25.0 | 28.0 | 24.9 | 0.212 | 25.5 | 25.0 | 0.953 | 27.5 | 24.9 | 0.129 | 25.0 | 25.0 | 0.568 |
GGT,b,e median | 23.0 | 26.0 | 21.6 | 0.278 | 24.0 | 21.1 | 0.423 | 29.0 d | 21.0 d | 0.047 d | 29.0 | 21.1 | 0.108 |
Low C3,c % | 47.6 | 65.5 d | 43.2 d | 0.038 d | 58.1 | 44.8 | 0.227 | 54.2 | 46.3 | 0.511 | 61.5 | 44.6 | 0.134 |
Low C4,c % | 34.7 | 37.9 | 33.9 | 0.670 | 38.7 | 33.6 | 0.672 | 37.5 | 34.1 | 0.816 | 38.4 | 33.9 | 0.656 |
CRP,b median | 0.38 | 0.30 | 0.40 | 0.771 | 0.28 | 0.42 | 0.454 | 0.25 | 0.42 | 0.379 | 26.0 | 25.9 | 0.803 |
ESR,b median | 24.0 | 25.0 | 24.0 | 0.616 | 22.0 | 25.0 | 0.740 | 21.5 | 25.0 | 0.572 | 23.0 | 24.5 | 0.819 |
Autoantibodies | |||||||||||||
High anti-Sm,c % | 33.7 | 63.3 d | 27.1 d | 4 × 10 -3d | 70.6 d | 24.2 d | <10 -4d | 66.7 d | 28.1 d | 7 × 10 -3d | 60.7 d | 28.1 d | 0.002 d |
Increased anti- dsDNA in ELISA,c % | 42.3 | 70.0 d | 36.8 d | 0.002 d | 67.8 d | 36.4 d | 0.002 d | 75.0 d | 37.4 d | 7 × 10 -3d | 60.7 d | 39.3 d | 0.058 d |
Increased anti- dsDNA in RIA,c % | 56.4 | 76.7 d | 51.9 d | 0.015 d | 79.4 d | 50.4 d | 0.003 d | 83.3 d | 51.8 d | 0.004 d | 78.6 d | 51.9 d | 0.012 d |
Increased anti- U1-RNP in anamnesis,c % | 28.9 | 59.1 d | 21.7 d | 0.001 d | 50.0 d | 23.3 d | 0.021 d | 62.5 d | 23.5 d | 0.003 d | 54.5 d | 22.7 d | 0.007 d |
Increased anti- nucleosomes,c % | 50.9 | 60.0 | 48.9 | 0.315 | 64.7 | 47.3 | 0.084 | 62.5 | 48.9 | 0.271 | 70.4 d | 47.1 d | 0.035 d |
Increased anti- Ro/SS-A,c % | 40.5 | 50.0 | 38.3 | 0.304 | 41.2 | 40.3 | 1.000 | 37.5 | 41.0 | 0.824 | 39.3 | 40.7 | 1.000 |
Increased anti- La/SS-B,c % | 12.3 | 20.0 | 10.5 | 0.213 | 8.82 | 13.2 | 0.769 | 0.00 d | 14.4 d | 0.046 d | 3.57 | 14.1 | 0.203 |